Document detail
ID

doi:10.1007/s12035-022-02742-5...

Author
Handley, Emily E. Reale, Laura A. Chuckowree, Jyoti A. Dyer, Marcus S. Barnett, Grace L. Clark, Courtney M. Bennett, William Dickson, Tracey C. Blizzard, Catherine A.
Langue
en
Editor

Springer

Category

Neurology

Year

2022

listing date

12/8/2022

Keywords
dendritic spine amyotrophic lateral sclerosis tdp-43 estrogen neuroplasticity disease
Metrics

Abstract

Amyotrophic lateral sclerosis (ALS) attacks the corticomotor system, with motor cortex function affected early in disease.

Younger females have a lower relative risk of succumbing to ALS than males and older females, implicating a role for female sex hormones in disease progression.

However, the mechanisms driving this dimorphic incidence are still largely unknown.

We endeavoured to determine if estrogen mitigates disease progression and pathogenesis, focussing upon the dendritic spine as a site of action.

Using two-photon live imaging we identify, in the prp TDP-43^A315T mouse model of ALS, that dendritic spines in the male motor cortex have a reduced capacity for remodelling than their wild-type controls.

In contrast, females show higher capacity for remodelling, with peak plasticity corresponding to highest estrogen levels during the estrous cycle.

Estrogen manipulation through ovariectomies and estrogen replacement with 17β estradiol in vivo was found to significantly alter spine density and mitigate disease severity.

Collectively, these findings reveal that synpatic plasticity is reduced in ALS, which can be amelioriated with estrogen, in conjuction with improved disease outcomes.

Handley, Emily E.,Reale, Laura A.,Chuckowree, Jyoti A.,Dyer, Marcus S.,Barnett, Grace L.,Clark, Courtney M.,Bennett, William,Dickson, Tracey C.,Blizzard, Catherine A., 2022, Estrogen Enhances Dendrite Spine Function and Recovers Deficits in Neuroplasticity in the prpTDP-43^A315T Mouse Model of Amyotrophic Lateral Sclerosis, Springer

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw